Expertise in
3
conditions

Claas T. Ulrich

Berlin, BE, DE 
Expertise in
3
conditions
Berlin, BE, DE 

Overview

Claas Ulrich practices practicing medicine in Berlin, Germany.

Ulrich is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Actinic Keratosis, Bowen's Disease, Basal Cell Skin Cancer, and Cerebrospinal Fluid Leak.

They are actively involved in clinical research, co-authoring 68 peer reviewed articles and participating in 2 clinical trials.

Locations

Berlin, BE 10117, Germany
Other Locations
Kiel, SH, Germany
Hannover, NI, Germany
Mitte, BE 10117, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Drug: Vismodegib
Study Phase: Phase 2
View 1 Less Clinical Trial

68 Total Publications

The Role of General Practitioners in Actinic Keratosis Management in Europe: A Dermato-Oncologists Initiative.
The Role of General Practitioners in Actinic Keratosis Management in Europe: A Dermato-Oncologists Initiative.
Journal: Journal of clinical medicine
Published: June 30, 2026

Frequently Asked Questions about Claas T. Ulrich

Is Claas T. Ulrich a top-rated expert for Actinic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Claas T. Ulrich is classified as an Distinguished expert for Actinic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Claas T. Ulrich participate in research or clinical trials?

Yes. Claas T. Ulrich has published 68 articles and abstracts on conditions like Actinic Keratosis. You can view a list of Claas T. Ulrich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ulrich's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile